- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Interventions
- SENTI-202
- Biological
- Lead sponsor
- Senti Biosciences
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2040
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
- Interventions
- Not listed
- Lead sponsor
- Adela, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib (Velcade)
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Refractory Multiple Myeloma
- Interventions
- Aurora A kinase inhibitor MLN8237, bortezomib
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Selinexor 40 mg
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- AUY922, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Cancer
- Interventions
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 38 more
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Standard of care
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Weeks and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Graft vs Host Disease, Hematologic Neoplasms, Lymphoma, Myelodysplastic Syndromes, Myeloid Leukemia
- Interventions
- Peripheral blood progenitor cell transplant
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 56
- States / cities
- Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
- Conditions
- Cancer
- Interventions
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Biological · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse, Other B Cell Lymphoma in Relapse, Plasma Cell Leukemia
- Interventions
- SNS01-T
- Biological
- Lead sponsor
- Senesco Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Rochester, Minnesota • Hackensack, New Jersey + 2 more
- Conditions
- Relapsed Refractory Multiple Myeloma
- Interventions
- NEXI-002 T Cells
- Biological
- Lead sponsor
- NexImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 6
- States / cities
- Duarte, California • Orlando, Florida • Boston, Massachusetts + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- PT-112
- Drug
- Lead sponsor
- Promontory Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 4 more
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
- Interventions
- Dasatinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 100
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- aflibercept
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 6
- States / cities
- Manhasset, New York • New York, New York • The Bronx, New York
- Conditions
- Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- umbilical cord blood transplantation
- Procedure
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- I-131-CLR1404, dexamethasone
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Maywood, Illinois • Detroit, Michigan + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- bb2121, Lenalomide, Talquetamab
- Biological · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Interventions
- arsenic trioxide, ascorbic acid, melphalan, chemosensitization/potentiation, chemotherapy
- Drug · Procedure
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- Glendale, Arizona • Bakersfield, California • Campbell, California + 16 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Dexamethasone, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Belumosudil mesylate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas